Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists

Background: Mesalazine is among the medications most prescribed by gastroenterologists, with variable and controversial use in different settings. We aimed to explore the use of mesalazine in the clinical practice of young gastroenterologists. Methods: A web-based electronic survey was distributed to all participants of the National Meeting of the Italian Young Gastroenterologist and Endoscopist Association. Results: A total of 101 participants took part in the survey, with a majority (54.4%) being aged >30 years, 63.4% of whom were trainees in academic hospitals, and 69.3% of whom were involved in the clinical management of inflammatory bowel disease (IBD). While both non-dedicated and IBD physicians generally agreed on the appropriate dose of mesalazine for mild ulcerative colitis (UC), significant differences were observed between the two groups for moderate-severe ulcerative colitis (UC). Additionally, in IBD patients who were starting immuno-modulators and/or biologics, 80% of IBD-dedicated physicians continued to prescribe mesalazine, compared to 45.2% of non-dedicated physicians (p = 0.002). Indeed, 48.4% of non-dedicated IBD physicians did not acknowledge mesalazine for colorectal cancer chemoprevention. With regards to Crohn’s disease, it is mainly used by 30.1% of IBD physicians for preventing postoperative recurrence of Crohn’s disease. Finally, 57.4% used mesalazine for symptomatic uncomplicated diverticular disease, and 84.2% did not recommend its use for irritable bowel syndrome. Conclusions: This survey showed heterogeneous behaviors in the daily use of mesalazine, mainly in the management of IBD. Educational programs and novel studies are needed to clarify its use.

[1]  M. Toruner,et al.  Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility , 2022, United European gastroenterology journal.

[2]  G. Barbara,et al.  Pathophysiology of Diverticular Disease: From Diverticula Formation to Symptom Generation , 2022, International journal of molecular sciences.

[3]  S. Sestito,et al.  Role of inflammation in pediatric irritable bowel syndrome , 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[4]  A. Moschen,et al.  Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis , 2021, Scandinavian journal of gastroenterology.

[5]  S. Danese,et al.  Breaking through the therapeutic ceiling: what will it take? , 2021, Gastroenterology.

[6]  A. Amiot,et al.  Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus , 2021, Digestive and Liver Disease.

[7]  G. Barbara,et al.  Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier , 2021, Frontiers in Nutrition.

[8]  V. Andersen,et al.  The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study , 2020, United European gastroenterology journal.

[9]  L. Peyrin-Biroulet,et al.  Patient’s profiling for therapeutic management of inflammatory bowel disease: a tailored approach , 2020, Expert review of gastroenterology & hepatology.

[10]  C. Le Berre,et al.  Modern use of 5-aminosalicylic acid compounds for ulcerative colitis , 2020, Expert opinion on biological therapy.

[11]  L. Stassen,et al.  ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. , 2019, Journal of Crohn's & colitis.

[12]  G. Barbara,et al.  Nerve fiber overgrowth in patients with symptomatic diverticular disease , 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[13]  Sha Li,et al.  Effectiveness of mesalazine to treat irritable bowel syndrome , 2019, Medicine.

[14]  F. Pace,et al.  Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry , 2019, United European gastroenterology journal.

[15]  F. Manguso,et al.  Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[16]  B. Feagan,et al.  Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews. , 2018, Inflammatory bowel diseases.

[17]  S. Hajibandeh,et al.  Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta‐analysis with trial sequential analysis of randomized controlled trials , 2018, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[18]  V. Andersen,et al.  Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study , 2018, Gut.

[19]  Siddharth Singh,et al.  Natural History of Adult Ulcerative Colitis in Population‐based Cohorts: A Systematic Review , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  G. Barbara,et al.  Treatment of Diverticular Disease With Aminosalicylates: The Evidence , 2016, Journal of clinical gastroenterology.

[21]  P. Malfertheiner,et al.  Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical Trials , 2016, Journal of clinical gastroenterology.

[22]  P. Brigidi,et al.  Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease , 2016, Gut.

[23]  G. Marasco,et al.  Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon , 2016, Digestive Diseases and Sciences.

[24]  F. Bazzoli,et al.  Randomised controlled trial of mesalazine in IBS , 2014, Gut.

[25]  P. Portincasa,et al.  Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – a double‐blind, randomised, placebo‐controlled study , 2013, Alimentary pharmacology & therapeutics.

[26]  R. Mueller,et al.  Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo‐controlled study , 2013, Alimentary pharmacology & therapeutics.

[27]  V. Annese,et al.  Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  J. Gisbert,et al.  Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain. , 2010, Journal of Crohn's & colitis.

[29]  W. Sandborn,et al.  A comparison of budesonide and mesalamine for active Crohn's disease. , 1999, Gastroenterology.

[30]  G. Porro,et al.  Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. , 1999, Gastroenterology.

[31]  D. Jewell,et al.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. , 1998, The New England journal of medicine.

[32]  D. Jewell,et al.  A Comparison of Budesonide and Mesalamine for Active Crohn's Disease , 1998 .

[33]  I. Beck,et al.  Oral 5-ASA Versus Prednisone in Short Term Treatment of Crohn's Disease: A Multicentre Controlled Trial , 1990 .